Evaluation of response after stereotactic body radiotherapy for hepatocellular carcinoma
- 24 October 2011
- Vol. 118 (12), 3191-3198
- https://doi.org/10.1002/cncr.26404
Abstract
BACKGROUND: Hepatocellular carcinoma (HCC) is increasing in incidence due to hepatitis C. Stereotactic body radiotherapy (SBRT) is a noninvasive, effective therapy in the management of liver malignancies. The authors evaluated radiological response in 26 patients with HCC treated with SBRT at Indiana University. METHODS: Between March 2005 and June 2008, 26 patients with HCC who were not surgical candidates were enrolled in a phase 1 to 2 trial. Eligibility criteria included solitary tumors ≤ 6 cm or up to 3 lesions with sum diameters ≤ 6 cm, and well‐compensated cirrhosis. All patients had imaging before, at 1 to 3 months, and every 3 to 6 months after SBRT. RESULTS: Patients received 3 to 5 fractions of SBRT. Median SBRT dose was 42 Gray (Gy) (range: 24‐48 Gy). Median follow‐up was 13 months. Per Response Evaluation Criteria in Solid Tumors (RECIST), 4 patients had a complete response (CR), 15 had a partial response (PR), and 7 achieved stable disease (SD) at 12 months. One patient with SD experienced progression marginal to the treated area. The overall best response rate (CR + PR) was 73%. In comparison, by European Association for the Study of the Liver (EASL) criteria, 18 of 26 patients had ≥ 50% nonenhancement at 12 months. Thirteen of 18 demonstrated 100% nonenhancement, being > 50% in 5 patients. Kaplan‐Meier 1‐ and 2‐year survival estimates were 77% and 60%, respectively. CONCLUSIONS: SBRT is effective therapy for patients with HCC with an overall best response rate (CR + PR) of 73%. Nonenhancement on imaging, a surrogate for ablation, may be a more useful indicator than size reduction in evaluating HCC response to SBRT in the first 6 to 12 months, supporting EASL criteria. Cancer 2012;118: 3191–98. © 2011 American Cancer Society.Keywords
This publication has 24 references indexed in Scilit:
- Evaluation of tumor response after locoregional therapies in hepatocellular carcinomaCancer, 2009
- Management of hepatocellular carcinomaJournal of Hepatology, 2005
- A phase I trial of stereotactic body radiation therapy (SBRT) for liver metastasesInternational Journal of Radiation Oncology*Biology*Physics, 2005
- A follow-up analysis of the pattern and predictors of dropout from the waiting list for liver transplantation in patients with hepatocellular carcinoma: Implications for the current organ allocation policyLiver Transplantation, 2003
- Systematic review of randomized trials for unresectable hepatocellular carcinoma: Chemoembolization improves survivalJournal of Hepatology, 2003
- Clinical Management of Hepatocellular Carcinoma. Conclusions of the Barcelona-2000 EASL ConferenceJournal of Hepatology, 2001
- New Guidelines to Evaluate the Response to Treatment in Solid TumorsJNCI Journal of the National Cancer Institute, 2000
- Liver Transplantation for the Treatment of Small Hepatocellular Carcinomas in Patients with CirrhosisThe New England Journal of Medicine, 1996
- The use of 3-D dose volume analysis to predict radiation hepatitisInternational Journal of Radiation Oncology*Biology*Physics, 1992
- Tumor size determines the efficacy of percutaneous ethanol injection for the treatment of small hepatocellular carcinomaJournal of Hepatology, 1992